Moderna (MRNA) Stock Forecast & Price Target

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

• Morgan Stanley recently raised its price target to $95 but retained an "equal weight" rating, which represents a potential downside of over 50% from the current stock price of $196.48, suggesting that the recent surge may have outpaced the company's fundamentals.
• The consensus rating for Moderna, Inc. remains "Hold" with an average price target of $78.17, which is significantly lower than the current market price, indicating that many sell-side analysts believe the stock is overvalued relative to its projected earnings.
• Insiders have sold 118,882 shares of company stock worth approximately $16.86 million over the last 90 days, including significant sales by President Stephen Hoge and other executives, which may signal a lack of confidence in the stock's future performance from those closest to the company.
• Moderna, Inc. continues to report negative earnings, with a loss of $1.97 per share in the most recent quarter and a negative net margin of 141.43%, indicating that the company is still spending significantly more than it is generating in revenue.
• Short interest in the stock remains notable, with 32,872,787 shares shorted as of the most recent record date, representing a short percentage of float of approximately 9.23%, which suggests that a portion of the market is betting against the stock's price appreciation.